Compare IDT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | ERAS |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | IDT | ERAS |
|---|---|---|
| Price | $50.82 | $15.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 106.9K | ★ 3.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | N/A | ★ 16.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.35 | $1.01 |
| 52 Week High | $71.12 | $16.00 |
| Indicator | IDT | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 74.61 |
| Support Level | $50.02 | $1.46 |
| Resistance Level | $52.24 | N/A |
| Average True Range (ATR) | 1.09 | 0.92 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 69.59 | 84.91 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.